Morgan Stanley
ACHL

Morgan Stanley’s Achilles Therapeutics ACHL Stock Holding History

Morgan Stanley’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,731
Closed -$38.5K – 8277
2024
Q4 		$38.5K Buy
33,731
+17,300
+105% +$17.8K ﹤0.01% 6369
2024
Q3 		$16.8K Buy
16,431
+7,500
+84% +$6.01K ﹤0.01% 6552
2024
Q2 		$7.28K Sell
8,931
-9,270
-51% -$8.15K ﹤0.01% 6763
2024
Q1 		$22.8K Buy
18,201
+18,161
+45,403% +$19.6K ﹤0.01% 6450
2023
Q4 		$36 Sell
40
-49,980
-100% -$42.9K ﹤0.01% 7717
2023
Q3 		$45.5K Sell
50,020
-22,733
-31% -$21.6K ﹤0.01% 6201
2023
Q2 		$68.8K Sell
72,753
-210,906
-74% -$200K ﹤0.01% 6091
2023
Q1 		$272K Buy
+283,659
New +$307K ﹤0.01% 5565
2022
Q4 		– Sell
-7,155
Closed -$16K – 7985
2022
Q3 		$16K Buy
7,155
+819
+13% +$2.32K ﹤0.01% 6900
2022
Q2 		$16K Buy
6,336
+115
+2% +$284 ﹤0.01% 7080
2022
Q1 		$18K Sell
6,221
-128
-2% -$454 ﹤0.01% 7198
2021
Q4 		$32K Buy
+6,349
New +$38.4K ﹤0.01% 7013

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Morgan Stanley's ACHL Position: Q1 2025 in Review

Morgan Stanley sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 33,731 shares — an estimated $38.5K sold.

Morgan Stanley first reported a position in ACHL in Q4 2021 and held it in 12 quarters. The position peaked at $272K in Q1 2023. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Morgan Stanley reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 33,731 Achilles Therapeutics shares in Q1 2025, an estimated $38.5K.
  • Morgan Stanley first reported a position in Achilles Therapeutics in Q4 2021 and held it in 12 quarters.
  • Morgan Stanley's Achilles Therapeutics position peaked at $272K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.